LINEZOLID-ASSOCIATED PERIPHERAL NEUROPATHY IN DRUG-RESISTANT TUBERCULOSIS: A CLINICAL AND ELECTROPHYSIOLOGICAL ASSESSMENT

Authors

  • Dr Dhaval Gajera
  • Dr Devendrakumar Rabari
  • Dr. Chandani J Shah

DOI:

https://doi.org/10.53555/dq11ws92

Keywords:

Linezolid, Drug-resistant tuberculosis, Peripheral neuropathy, EMG–NCV

Abstract

Background:
Linezolid is a key component of all-oral longer regimens for drug-resistant tuberculosis (DR-TB), but its use is frequently limited by neurotoxicity.

Objective: To evaluate the incidence, clinical and electrophysiological characteristics, time to onset, severity, and management outcomes of linezolid-associated peripheral neuropathy in patients receiving linezolid-containing DR-TB regimens.

Methods: This prospective observational study included adult DR-TB patients initiated on linezolid at a tertiary DR-TB Centre. Patients were monitored clinically for neuropathic symptoms and underwent neurological examination and EMG–NCV testing when neuropathy was suspected. Neuropathy was classified as mild, moderate, or severe based on clinical and electrophysiological findings. Data on exposure duration, pattern of nerve involvement, and management decisions were recorded and analysed descriptively.

Results: Among 50 patients receiving linezolid, peripheral neuropathy developed in 26 (52%). Moderate neuropathy was most frequent (57.7%), followed by mild (30.8%) and severe forms (11.5%). EMG–NCV confirmed motor-predominant neuropathy in 40%, with sensory, autonomic, and mixed patterns in 16%, 4%, and 2% respectively. Neuropathy occurred early, with 73.1% of cases developing within 0–2 weeks of treatment and the remainder between 2–6 weeks. All affected patients required permanent discontinuation of linezolid despite initial dose reduction attempts.

Conclusion: Peripheral neuropathy occurred commonly and developed rapidly among DR-TB patients receiving linezolid-containing regimens. Motor involvement predominated, and most cases were moderate in severity. Early onset and the need for permanent drug withdrawal highlight the importance of proactive neurological monitoring and individualized risk assessment in patients receiving linezolid.

Author Biographies

  • Dr Dhaval Gajera

    Senior Resident, Department of Respiratory Medicine, ESIC Medical College, Naroda-Bapunagar, Ahmedabad, Gujarat, India

  • Dr Devendrakumar Rabari

    CPS student, Department of Respiratory Medicine, Shree Giriraj Hospital, Rajkot, Gujarat, India

  • Dr. Chandani J Shah

    Assistant Professor, Department of Neurology, Narendra Modi Medical College, Ahmedabad, Gujarat, India

References

1. Seung KJ, Keshavjee S, Rich ML. Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis. Cold Spring Harb Perspect Med. 2015 Apr 27;5(9):a017863.

2. Chen RH, Burke A, Cho JG, Alffenaar JW, Davies Forsman L. New Oxazolidinones for Tuberculosis: Are Novel Treatments on the Horizon? Pharmaceutics. 2024 Jun 17;16(6):818.

3. McDowell A, Haas M, Seaworth B, Wilson JW, Patrawalla A, Haley C, Lauzardo M, de Bruyn M, Goswami ND. Linezolid use for the treatment of multidrug-resistant tuberculosis, TB centers of excellence, United States, 2013–2018. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases. 2021 Feb 1;22:100201.

4. Imperial MZ, Nedelman JR, Conradie F, Savic RM. Proposed Linezolid Dosing Strategies to Minimize Adverse Events for Treatment of Extensively Drug-Resistant Tuberculosis. Clin Infect Dis. 2022 May 30;74(10):1736-1747.

5. Bressler AM, Zimmer SM, Gilmore JL, Somani J. Peripheral neuropathy associated with prolonged use of linezolid. Lancet Infect Dis. 2004 Aug;4(8):528-31.

6. Miller HV, Cao AA, McClelland CM, Lee MS. Linezolid optic neuropathy. Curr Opin Ophthalmol. 2023 Nov 01;34(6):481-486.

7. Bano S, Nawaz A, Numan A, Hassan MA, Shafique MBA. A Case Report and Literature Review of the Outcome of Linezolid-Induced Optic and Peripheral Neuropathy in Patients With Multidrug-Resistant Pulmonary TB. Front Neurol. 2022 Jun 24;13:908584.

8. Zhang P, Li W, Liu M, Zhan S, Zhang H, Deng G, Chen X. Linezolid-associated neuropathy in patients with MDR/XDR tuberculosis in Shenzhen, China. Infect Drug Resist. 2022;15:2617-2624.

9. Jaspard M, Butel N, El Helali N, Marigot-Outtandy D, Guillot H, Peytavin G, Veziris N, Bodaghi B, Flandre P, Petitjean G, Caumes E, Pourcher V. Linezolid-associated neurologic adverse events in patients with multidrug-resistant tuberculosis, France. Emerg Infect Dis. 2020;26(8):1792-1800.

10. Saibannavar A, Kumbhar N, Kaur G. Linezolid associated peripheral neuropathy in patients with MDR/XDR tuberculosis. Int J Med Sci Clin Res Rev. 2024;7(2):391-395.

11. Anger HA, Dworkin F, Sharma S, Munsiff SS, Nilsen DM, Ahuja SD. Linezolid use for treatment of multidrug-resistant and extensively drug-resistant tuberculosis, New York City, 2000–06. Journal of antimicrobial chemotherapy. 2010 Apr 1;65(4):775-83.

12. Maniyar A, Chheda A, Mahto AP, Chaudhary GS, Jagiasi KA, Ojha PT, Singh RK, Nagendra S, Shah AG, Aipu BK, Bagadia HP. Linezolid induced peripheral neuropathy in multidrug resistant tuberculosis – A prospective observational study. Indian J Neurol. 2025;6(1):142.03-142.04.

1. Seung KJ, Keshavjee S, Rich ML. Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis. Cold Spring Harb Perspect Med. 2015 Apr 27;5(9):a017863.

2. Chen RH, Burke A, Cho JG, Alffenaar JW, Davies Forsman L. New Oxazolidinones for Tuberculosis: Are Novel Treatments on the Horizon? Pharmaceutics. 2024 Jun 17;16(6):818.

3. McDowell A, Haas M, Seaworth B, Wilson JW, Patrawalla A, Haley C, Lauzardo M, de Bruyn M, Goswami ND. Linezolid use for the treatment of multidrug-resistant tuberculosis, TB centers of excellence, United States, 2013–2018. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases. 2021 Feb 1;22:100201.

4. Imperial MZ, Nedelman JR, Conradie F, Savic RM. Proposed Linezolid Dosing Strategies to Minimize Adverse Events for Treatment of Extensively Drug-Resistant Tuberculosis. Clin Infect Dis. 2022 May 30;74(10):1736-1747.

5. Bressler AM, Zimmer SM, Gilmore JL, Somani J. Peripheral neuropathy associated with prolonged use of linezolid. Lancet Infect Dis. 2004 Aug;4(8):528-31.

6. Miller HV, Cao AA, McClelland CM, Lee MS. Linezolid optic neuropathy. Curr Opin Ophthalmol. 2023 Nov 01;34(6):481-486.

7. Bano S, Nawaz A, Numan A, Hassan MA, Shafique MBA. A Case Report and Literature Review of the Outcome of Linezolid-Induced Optic and Peripheral Neuropathy in Patients With Multidrug-Resistant Pulmonary TB. Front Neurol. 2022 Jun 24;13:908584.

8. Zhang P, Li W, Liu M, Zhan S, Zhang H, Deng G, Chen X. Linezolid-associated neuropathy in patients with MDR/XDR tuberculosis in Shenzhen, China. Infect Drug Resist. 2022;15:2617-2624.

9. Jaspard M, Butel N, El Helali N, Marigot-Outtandy D, Guillot H, Peytavin G, Veziris N, Bodaghi B, Flandre P, Petitjean G, Caumes E, Pourcher V. Linezolid-associated neurologic adverse events in patients with multidrug-resistant tuberculosis, France. Emerg Infect Dis. 2020;26(8):1792-1800.

10. Saibannavar A, Kumbhar N, Kaur G. Linezolid associated peripheral neuropathy in patients with MDR/XDR tuberculosis. Int J Med Sci Clin Res Rev. 2024;7(2):391-395.

11. Anger HA, Dworkin F, Sharma S, Munsiff SS, Nilsen DM, Ahuja SD. Linezolid use for treatment of multidrug-resistant and extensively drug-resistant tuberculosis, New York City, 2000–06. Journal of antimicrobial chemotherapy. 2010 Apr 1;65(4):775-83.

12. Maniyar A, Chheda A, Mahto AP, Chaudhary GS, Jagiasi KA, Ojha PT, Singh RK, Nagendra S, Shah AG, Aipu BK, Bagadia HP. Linezolid induced peripheral neuropathy in multidrug resistant tuberculosis – A prospective observational study. Indian J Neurol. 2025;6(1):142.03-142.04.

Downloads

Published

2025-11-19

How to Cite

Dr Dhaval Gajera, Dr Devendrakumar Rabari, & Dr. Chandani J Shah. (2025). LINEZOLID-ASSOCIATED PERIPHERAL NEUROPATHY IN DRUG-RESISTANT TUBERCULOSIS: A CLINICAL AND ELECTROPHYSIOLOGICAL ASSESSMENT. Journal of Population Therapeutics and Clinical Pharmacology, 32(10), 944-949. https://doi.org/10.53555/dq11ws92
More Citation Formats

Issue

Section

Articles

How to Cite

Dr Dhaval Gajera, Dr Devendrakumar Rabari, & Dr. Chandani J Shah. (2025). LINEZOLID-ASSOCIATED PERIPHERAL NEUROPATHY IN DRUG-RESISTANT TUBERCULOSIS: A CLINICAL AND ELECTROPHYSIOLOGICAL ASSESSMENT. Journal of Population Therapeutics and Clinical Pharmacology, 32(10), 944-949. https://doi.org/10.53555/dq11ws92